A new reform under Trump’s administration aims to make more drugs available over-the-counter, stirring both hope and debate among conservatives.
Story Snapshot
- Trump’s healthcare plan proposes OTC drug access to cut costs
- Most Favored Nation pricing deals codified to lower drug prices
- Focus on enhancing transparency and eliminating PBM kickbacks
- Plan announced amid rising ACA premiums and subsidy debates
Trump’s Plan to Expand Over-the-Counter Drug Access
President Donald Trump has introduced “The Great Healthcare Plan,” a comprehensive proposal that includes expanding access to over-the-counter (OTC) medications. Announced on January 15, 2026, the plan aims to lower prescription costs and make healthcare more affordable for Americans. By making more medications available without a prescription, the plan seeks to empower consumers and reduce their healthcare expenses. However, the specifics of which drugs will be made available remain unclear.
Beyond OTC access, Trump’s plan codifies Most Favored Nation (MFN) pricing agreements with pharmaceutical companies. These agreements aim to ensure that Americans pay the lowest drug prices available globally, countering past policies seen as favoring corporate profits over consumer affordability. Sixteen out of seventeen targeted pharmaceutical companies have already signed onto these voluntary agreements, signaling a significant shift in drug pricing strategy.
Impact on Pharmacy Benefit Managers and Insurers
Pharmacy Benefit Managers (PBMs) and insurers are directly targeted by the plan, which seeks to eliminate kickbacks and enhance transparency in healthcare pricing. By enforcing transparency mandates, the plan aims to hold these entities accountable for their pricing practices. This is expected to curb the “middlemen scams” that have historically inflated costs for consumers. Yet, the challenge remains in ensuring compliance, as past transparency regulations under Trump faced significant resistance and poor compliance.
The proposed reforms also include directing payments to individuals’ Health Savings Accounts (HSAs), aiming to give consumers more control over their healthcare expenditures. However, critics argue that the benefits may be limited to those with high-deductible plans, potentially leaving out a significant portion of the population. The Congressional Budget Office has been cited for potential savings, yet the feasibility of these projections remains under scrutiny.
Political and Economic Ramifications
Politically, Trump’s healthcare initiative seeks to strengthen his administration’s stance on affordability and consumer empowerment. The plan is positioned as a superior alternative to the Affordable Care Act, particularly amid ongoing subsidy debates and rising premiums. Economically, while the plan promises to reduce drug costs, there are concerns about its impact on pharmaceutical research and development, with some experts warning that MFN pricing could stifle innovation.
A Good Idea in Trump’s “Great Healthcare Plan”: Put More Drugs Over the Counter https://t.co/VY0RDCnDKm via @CatoInstitute
— Jeffrey A. Singer (@dr4liberty) January 15, 2026
Overall, Trump’s healthcare plan represents a significant shift in strategy, focusing on consumer empowerment and cost reduction. However, the success of the plan will depend on its execution and the ability to overcome potential hurdles, such as compliance with transparency mandates and the balance between cost savings and innovation in drug development.
Sources:
Trump’s Great Healthcare Plan: Affordability and ACA
Health Policy and the 2024 Election
